Daniel Lesueur Sells 16,902 Shares of Health Catalyst, Inc. (NASDAQ:HCAT) Stock

Health Catalyst, Inc. (NASDAQ:HCAT - Get Free Report) COO Daniel Lesueur sold 16,902 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $4.52, for a total transaction of $76,397.04. Following the completion of the sale, the chief operating officer now owns 216,250 shares in the company, valued at approximately $977,450. This trade represents a 7.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Daniel Lesueur also recently made the following trade(s):

• On Wednesday, February 5th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The stock was sold at an average price of $5.76, for a total value of $30,003.84.
• On Monday, January 6th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The shares were sold at an average price of $7.51, for a total value of $39,119.59.

Health Catalyst Trading Down 7.2 %

HCAT stock traded down $0.32 during mid-day trading on Thursday, reaching $4.11. The company had a trading volume of 505,074 shares, compared to its average volume of 885,958. The company has a market capitalization of $288.57 million, a PE ratio of -3.04 and a beta of 1.41. The firm has a 50 day moving average of $5.56 and a 200 day moving average of $7.10. Health Catalyst, Inc. has a 12 month low of $3.76 and a 12 month high of $9.24. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.41 and a quick ratio of 1.41.

Remove Ads

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on HCAT shares. Piper Sandler cut their target price on Health Catalyst from $12.00 to $8.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 11th. Wells Fargo & Company reduced their target price on shares of Health Catalyst from $13.00 to $10.00 and set an "overweight" rating on the stock in a research note on Tuesday, January 21st. Stifel Nicolaus lowered their target price on shares of Health Catalyst from $10.00 to $5.00 and set a "hold" rating for the company in a report on Thursday, February 27th. Canaccord Genuity Group cut their price target on shares of Health Catalyst from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, January 21st. Finally, Stephens reduced their price objective on shares of Health Catalyst from $7.00 to $5.00 and set an "equal weight" rating on the stock in a research report on Thursday, March 6th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $9.27.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Quantbot Technologies LP bought a new stake in Health Catalyst during the 4th quarter valued at $29,000. Group One Trading LLC raised its holdings in shares of Health Catalyst by 107.6% in the fourth quarter. Group One Trading LLC now owns 4,360 shares of the company's stock valued at $31,000 after acquiring an additional 2,260 shares in the last quarter. Quest Partners LLC bought a new stake in shares of Health Catalyst in the third quarter valued at about $34,000. Aquatic Capital Management LLC purchased a new stake in Health Catalyst in the fourth quarter worth about $63,000. Finally, Stoneridge Investment Partners LLC bought a new position in Health Catalyst during the 4th quarter worth about $77,000. Institutional investors own 85.00% of the company's stock.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.